Lack of Cross-resistance to Fostriecin in a Human Small-cell Lung Carcinoma Cell Line Showing Topoisomerase II-related Drug Resistance

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1991 Jan 1

PMID 1657425

Citations 11

Authors

S de Jong

J G Zijlstra

N H Mulder

E G De Vries

Affiliations

Soon will be listed here.

Abstract

Cells exhibiting decreased topoisomerase II (Topo II) activity are resistant to several drugs that require Topo II as an intermediate. These drugs are cytotoxic due to the formation of a cleavable complex between the drug, Topo II and DNA. Fostriecin belongs to a new class of drugs that inhibit Topo II without inducing the formation of this cleavable complex. We tested fostriecin in three human small-cell lung carcinoma cell lines. GLC4 is the parent line. GLC4/ADR is the P-glycoprotein-negative multidrug-resistant subline, which is resistant to several Topo II inhibitors due to its decreased Topo II activity. GLC4/cDDP is the cisplatin-resistant subline, which displays increased Topo II activity. Topo II activity proved to be 100% in GLC4, 35% in GLC4/ADR and 130% in GLC4/cDDP. The fostriecin concentration causing inhibition of the growth of 50% of the cells (IC50) in the microculture tetrazolium assay following continuous incubation was 11.2, 4.1 and 14.9 microM, respectively. After 1-h incubations, the IC50 was 117.8, 101.3 and 219.8 microM, respectively. Our results indicate a relationship between Topo II activity and fostriecin sensitivity in these closely related cell lines. At least in vitro, fostriecin displayed the capacity to kill cells showing resistance to drugs due to decreased Topo II activity. There was no relationship between this capacity and an increase in the activity of the reduced-folate carrier system, the proposed mechanism for cellular entry of fostriecin, since we found no correlation between the cytotoxicity of fostriecin and that of methotrexate.

Citing Articles

Altering phosphorylation in cancer through PP2A modifiers.

Johnson H, Narayan S, Sharma A Cancer Cell Int. 2024; 24(1):11.

PMID: 38184584 PMC: 10770906. DOI: 10.1186/s12935-023-03193-1.

Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure.

Sagawa Y, Fujitoh A, Nishi H, Ito H, Yudate T, Isaka K Tumour Biol. 2010; 32(2):399-408.

PMID: 21113744 DOI: 10.1007/s13277-010-0133-6.

Phase I and pharmacokinetic study of fostriecin given as an intravenous bolus daily for five consecutive days.

Le L, Erlichman C, Pillon L, Thiessen J, Day A, Wainman N Invest New Drugs. 2004; 22(2):159-67.

PMID: 14739664 DOI: 10.1023/B:DRUG.0000011792.13160.b0.

Protein phosphatase 2A enhances activation of human immunodeficiency virus type 1 by phorbol myristate acetate.

Faulkner N, Lane B, Bock P, Markovitz D J Virol. 2003; 77(3):2276-81.

PMID: 12525665 PMC: 140936. DOI: 10.1128/jvi.77.3.2276-2281.2003.

Cytotoxicity of rhein, the active metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1.

van Gorkom B, Timmer-Bosscha H, de Jong S, van der Kolk D, Kleibeuker J, de Vries E Br J Cancer. 2002; 86(9):1494-500.

PMID: 11986786 PMC: 2375364. DOI: 10.1038/sj.bjc.6600255.

References

Moscow J, Cowan K . Multidrug resistance. J Natl Cancer Inst. 1988; 80(1):14-20. DOI: 10.1093/jnci/80.1.14. View

Danks M, Schmidt C, Cirtain M, Suttle D, Beck W . Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry. 1988; 27(24):8861-9. DOI: 10.1021/bi00424a026. View

Drake F, Hofmann G, Mong S, Bartus J, Hertzberg R, Johnson R . In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res. 1989; 49(10):2578-83. View

Scheithauer W, Von Hoff D, Clark G, Shillis J, Elslager E . In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay. Eur J Cancer Clin Oncol. 1986; 22(8):921-6. DOI: 10.1016/0277-5379(86)90057-x. View

de Jong S, Zijlstra J, De Vries E, Mulder N . Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 1990; 50(2):304-9. View

Boritzki T, Wolfard T, Besserer J, Jackson R, FRY D . Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol. 1988; 37(21):4063-8. DOI: 10.1016/0006-2952(88)90096-2. View

Liu L . DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989; 58:351-75. DOI: 10.1146/annurev.bi.58.070189.002031. View

Epstein R, Smith P . Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs. Cancer Res. 1988; 48(2):297-303. View

De Vries E, Meijer C, Timmer-Bosscha H, Berendsen H, de Leij L, Scheper R . Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. Cancer Res. 1989; 49(15):4175-8. View

10.

FRY D, Besserer J, Boritzki T . Transport of the antitumor antibiotic Cl-920 into L1210 leukemia cells by the reduced folate carrier system. Cancer Res. 1984; 44(8):3366-70. View

11.

Leopold W, Shillis J, Mertus A, Nelson J, Roberts B, Jackson R . Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues. Cancer Res. 1984; 44(5):1928-32. View

12.

Deffie A, Batra J, GOLDENBERG G . Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res. 1989; 49(1):58-62. View

13.

Morrow C, Cowan K . Mechanisms and clinical significance of multidrug resistance. Oncology (Williston Park). 1988; 2(10):55-63, 66-8. View

14.

Ferguson P, Fisher M, Stephenson J, Li D, Zhou B, Cheng Y . Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res. 1988; 48(21):5956-64. View

15.

Ross W, Sullivan D, Chow K . Altered function of DNA topoisomerases as a basis for antineoplastic drug action. Important Adv Oncol. 1988; :65-81. View

16.

Hospers G, Mulder N, de Jong B, de Ley L, Uges D, Scheper R . Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res. 1988; 48(23):6803-7. View

17.

Wang J . DNA topoisomerases. Annu Rev Biochem. 1985; 54:665-97. DOI: 10.1146/annurev.bi.54.070185.003313. View

18.

Zijlstra J, de Jong S, De Vries E, Mulder N . Topoisomerases, new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother. 1990; 7(1):11-8. DOI: 10.1007/BF03000485. View

19.

Spiridonidis C, Chatterjee S, Petzold S, Berger N . Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines. Cancer Res. 1989; 49(3):644-50. View

20.

Holm C, Goto T, Wang J, Botstein D . DNA topoisomerase II is required at the time of mitosis in yeast. Cell. 1985; 41(2):553-63. DOI: 10.1016/s0092-8674(85)80028-3. View